QRCode



Traders/Users: Online

2021/02/08

2 Best Biotech Stocks For This Week (Part I) 2021

 
by Jorge Aura

The biopharmaceutical sector is living a speculation moment. The general feeling among investors is that great advances with the fight against cancer are going to be produced and the existing medication will be improved. Some companies conduct promising studies against cancer. It is speculated that before 10 years we could have a substantial improvement in the partial cure of the most deadly cancers. Meanwhile, other companies are trying to improve the current medication for the retinal and macular degeneration and COVID19 vaccines. 

There are two companies that are making some spectacular progress in their studies. Ocugen Inc. (OCGN) and Salarius Pharmaceuticals Inc(SLRX).

In the next article I will write about the reasons to take a speculative position in these companies.


1. Ocugen Inc. 
is a biopharmaceutical company focused on discovering, developing and commercializing transformative therapies to treat blindness diseases. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many”. And our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy.


Pipeline Portfolio

                          (Source)



New catalyst

Last February 2, 2021, Ocugen Inc and Bharat Biotech Announce Execution of Definitive Agreement for the Commercialization of COVAXIN™ in the US Market.


Next Catalyst

- Phase III results of Covaxin early March 2021.


Fundamentals Analysis

OCGN Short Interest

SETTLEMENT DATE

SHORT INTEREST

AVG. DAILY SHARE VOLUME

DAYS TO COVER

01/15/2021

14,803,511

47,577,579

1

12/31/2020

17,658,831

187,375,800

1

12/15/2020

4,978,581

13,895,745

1



Analyst Research

Strong Buy           

Based on 4 analysts offering recommendations for ocgn in the                    last 3 months.


Chart Analysis


- Rsi marks an overbought. The stock is in a bullish channel. The MACD and Full STO marks an upward trend.



2. Salarius Pharmaceuticals Inc

It is an emerging biotechnology company developing targeted therapies to treat pediatric and other cancers, including advanced solid tumors. The lead compound Seclidemstat represents a potential paradigm shift in the treatment of cancer and we are initially targeting Ewing sarcoma, a devastating pediatric, adolescent and young adult bone cancer where no targeted therapies are currently available.

Salarius pharmaceutical ongoing two clinical trials with catalysts in 2021.

Salarius ongoing a Phase 1 trial in Ewing sarcoma. Ewing sarcoma is a devastating pediatric illness and represents a major unmet clinical need. Currently, chemotherapy, radiation and tumor resection surgery are the only options for patients, and in many cases the tumors reoccur or is in too delicate of a location to risk surgery. There is a 70-90% five-year mortality rate for patients whose tumors recur after treatment or who are initially diagnosed with metastatic disease. Translocations involving the EWS gene are the sole driver for over 85% of Ewing sarcoma, and the EWS protein must complex with LSD1 to induce a cancer phenotype. Seclidemstat blocks this LSD1-EWS interaction to reverse cancer pathology resulting in cures in animal models.

Phase 1 trial in advanced solid tumors enroll patients with advanced solid tumors who have progressed on prior therapy, for example patients with prostate, breast, ovarian, lung and other sarcomas. Depending on the cancer, LSD1 can associate with a myriad of proteins to drive tumor growth. For instance, in prostate cancer LSD1 can associate with the androgen receptor to activate genes that promote cancer cell growth and metastasis. Seclidemstat is able to block these interactions and reduce tumor burden.



Pipeline Portfolio

                          (Source)



Next Catalyst

- The company announced in its presentation to investors that it has the following catalysts for 2021:


                          (Source)



Fundamentals Analysis

SLRX Short Interest

SETTLEMENT DATE

SHORT INTEREST

AVG. DAILY SHARE VOLUME

DAYS TO COVER

01/15/2021

614,252

1,797,441

1

12/31/2020

572,831

510,666

1.121733

12/15/2020

466,549

2,440,984

1



Analyst Research

Strong Buy

Based on 2 analysts offering recommendations for slrx in the last 3 months.


Chart Analysis



 
- The MACD and Full STO marks an upward trend. RSI is in a good position. The stock is in a bullish channel.The moving averages have marked an upward crossover or golden cross.

*Chart data sourced from stockcharts, all other data sourced from Nasdaq.com as well as the web of the previously mentioned company.

Disclosure: I am long SLRX. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article. Investors buy and/or sell at their own risk. I declare that I may day-trade any stock at any time mentioned in this article. For me "long" is until I sell and few tell you that. I do not "short" stocks and few tell you that too. I have zero connection to Wall Street and few tell you that too.
 

 

0 comentarios: